H.C. Wainwright adjusted the firm’s price target on Arqit Quantum (ARQQ) to $22 from $2 and keeps a Buy rating on the shares to reflect the ...
On Wednesday, Verrica Pharmaceuticals Inc (VRCA) stock saw a modest uptick, ending the day at $1.24 which represents a slight increase of $0.13 or 11.71% from the prior close of $1.11. The stock ...
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage ...
H.C. Wainwright lowered the firm’s price target on Lexicon (LXRX) to $4 from $6 and keeps a Buy rating on the shares. The company announced that following a “deficiencies preclude discussion ...
H.C. Wainwright has recently reduced Eyenovia Inc (EYEN) stock to Neutral rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 1, 2021, Northland Capital had initiated the ...
H.C. Wainwright initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a buy rating, citing its negative enterprise value. The investment bank said its rating was based on Vanda’s well ...
H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. The views and opinions expressed herein are the ...
Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...
Phunware (NASDAQ:PHUN) shares retreated 11% in Tuesday late morning trading after H.C. Wainwright & Co. downgraded the application software company to Neutral from Buy, as analyst Scott Buck ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback